文献速递肾癌与肾肿瘤

局限性非转移性肉瘤样肾细胞癌:一项经外部验证的31年研究

Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
PubMed 文献 · BJU Int · 2023-09-09

该研究纳入1988年6月至2019年3月接受部分或根治性肾切除术的564例局限性肾细胞癌患者,其中肉瘤样肾细胞癌(sRCC)204例、世界卫生组织/国际泌尿病理学会4级非sRCC 360例,比较两组各分期癌症特异性生存(CSS),并用III期ASSURE临床试验数据进行外部验证。中位随访31.5个月,sRCC组中位总生存和CSS分别为45个月和49个月,4级非sRCC组分别为102个月和152个月(P < 0.001);sRCC在各分期CSS均更差,pT1 sRCC的CSS差于pT3 4级非sRCC。

要点

  • sRCC组中位总生存45个月、CSS 49个月,4级非sRCC组分别为102个月、152个月(P < 0.001)。
  • 各分期sRCC的CSS均差于4级非sRCC,pT1 sRCC的CSS差于pT3 4级非sRCC。
  • ASSURE外部验证显示sRCC患者CSS更差(HR 1.63,95%CI 1.12-2.36;P = 0.01)。

核心结论

  • 局限性sRCC在各分期的CSS均差于4级非sRCC;阳性切缘、更高病理分期、使用微创手术和非透明细胞组织学为阴性生存预测因素。
  • sRCC即使处于低分期也是侵袭性变异型,需要警惕性监测并可能纳入辅助治疗试验。

研究设计与样本

  • 研究纳入1988年6月至2019年3月接受部分或根治性肾切除术的564例局限性肾细胞癌患者,其中sRCC 204例、世界卫生组织/国际泌尿病理学会4级非sRCC 360例。
  • 研究比较两组各分期的CSS,并使用III期ASSURE临床试验数据进行外部验证。
  • 统计方法包括Mann-Whitney U检验、卡方检验、Kaplan-Meier法评估CSS、总生存和無复发生存,Cox比例风险回归评估与肾细胞癌死亡相关的临床病理特征。

主要发现

  • 中位随访31.5个月,sRCC组与4级非sRCC组的中位总生存分别为45个月与102个月,中位CSS分别为49个月与152个月(P < 0.001)。
  • 各分期sRCC的CSS均差于4级非sRCC,pT1 sRCC的CSS差于pT3 4级非sRCC。
  • CSS的阴性预测因素包括肉瘤样特征、非透明细胞组织学、阳性切缘、更高分期(pT3/pT4)和使用微创手术。
  • ASSURE外部验证显示sRCC患者CSS更差(HR 1.63,95%CI 1.12-2.36;P = 0.01),但微创手术未显示更差结局(HR 1.39,95%CI 0.75-2.56;P = 0.30)。

临床怎么用

  • 作者认为sRCC即使处于低分期也是侵袭性变异型,需要警惕性监测并可能纳入辅助治疗试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate post-nephrectomy outcomes and predictors of cancer-specific survival (CSS) between patients with localised sarcomatoid renal cell carcinoma (sRCC) and those with Grade 4 RCC (non-sRCC), as most sRCC research focuses on advanced or metastatic disease with limited studies analysing outcomes of patients with localised non-metastatic sRCC. PATIENTS AND METHODS: A total of 564 patients with localised RCC underwent partial or radical nephrectomy between June 1988 to March 2019 for sRCC (n = 204) or World Health Organization/International Society of Urological Pathology Grade 4 non-sRCC (n = 360). The CSS at every stage between groups was assessed. Phase III ASSURE clinical trial data were used to externally validate the CSS findings. The Mann-Whitney U-test and chi-squared test compared outcomes and the Kaplan-Meier method evaluated CSS, overall survival (OS) and recurrence-free survival. Clinicopathological features associated with RCC death were evaluated using Cox proportional hazards regression. RESULTS: The median follow-up was 31.5 months. The median OS and CSS between the sRCC and Grade 4 non-sRCC groups was 45 vs 102 months and 49 vs 152 months, respectively (P < 0.001). At every stage, sRCC had worse CSS compared to Grade 4 non-sRCC. Notably, pT1 sRCC had worse CSS than pT3 Grade 4 non-sRCC. Negative predictors of CSS were sarcomatoid features, non-clear cell histology, positive margins, higher stage (pT3/pT4), and use of minimally invasive surgery (MIS). ASSURE external verification showed worse CSS in patients with sRCC (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.12-2.36; P = 0.01), but not worse outcomes in MIS surgery (HR 1.39, 95% CI 0.75-2.56; P = 0.30). CONCLUSIONS: Localised sRCC had worse CSS compared to Grade 4 non-sRCC at every stage. Negative survival predictors included positive margins, higher pathological stage, use of MIS, and non-clear cell histology. sRCC is an aggressive variant even at low stages requiring vigilant surveillance and possible inclusion in adjuvant therapy trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Blum KA, Silagy AW, Knezevic A, et al. Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study. BJU Int. 2023. PMID: 37589200. doi:10.1111/bju.16125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。